Last reviewed · How we verify
NCT04818970
Photo-Protection Trial (NB-UVB vs. Placebo) in High-risk Hospitalized COVID-19 Patients
NA trial testing Narrow Band ultraviolet B-Band Light in Covid19 in 30 participants. Completed in 1 December 2021.
31 October 2021
Quick facts
| Lead sponsor | Cytokind, Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 21 May 2021 |
| Primary completion | 31 October 2021 |
| Estimated completion | 1 December 2021 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Narrow Band ultraviolet B-Band Light
- non Narrow Band ultraviolet B-Band Light
Conditions studied
- Covid19 — all drugs for Covid19 →
- Corona Virus Infection — all drugs for Corona Virus Infection →
- Autoimmune Diseases — all drugs for Autoimmune Diseases →
- Coagulation Disorder, Blood — all drugs for Coagulation Disorder, Blood →
Sponsor
Cytokind, Inc.
Who can join
Adults 50 to 110, any sex, with Covid19 or Corona Virus Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study to evaluate the translational application of the safe and effective treatment of Narrow-Band Ultraviolet light B-band (NB-UVB) to high-risk COVID-19 patients in an effort to improve their immune and hemostatic imbalance to increase survival and improve outcomes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pilot phase results of a prospective, randomized controlled trial of narrowband ultraviolet B phototherapy in hospitalized COVID-19 patients.
Lau FH, Powell CE, Adonecchi G, Danos DM, et al · · 2022 · cited 10× · PMID 35638295 · DOI 10.1111/exd.14617
Verify or expand the search:
- PubMed search for NCT04818970
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Covid19
Currently open trials in the same condition.
- NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
- NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
- NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
- NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
- NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04818970 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cytokind, Inc.
- Last refreshed: 15 June 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04818970.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing